Clinical Trial Update: A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis. [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and tolerability of the CAN10 antibody in healthy subjects and in people with plaque psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• CAN10

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Healthy, Plaque Psoriasis | Phase 1 | Status: COMPLETED